Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Сцинтиграфия миокарда с 99mTc-пирофосфатом в диагностике амилоидоза сердца: место в диагностическом алгоритме, особенности выполнения и интерпретации исследования
Сцинтиграфия миокарда с 99mTc-пирофосфатом в диагностике амилоидоза сердца: место в диагностическом алгоритме, особенности выполнения и интерпретации исследования
Аншелес А.А., Насонова С.Н., Жиров И.В., Саидова М.А., Стукалова О.В., Терещенко С.Н., Сергиенко В.Б. Сцинтиграфия миокарда с 99mTc-пирофосфатом в диагностике амилоидоза сердца: место в диагностическом алгоритме, особенности выполнения и интерпретации исследования. Терапевтический архив. 2022;94(4):530–537. DOI: 10.26442/00403660.2022.04.201461
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье суммируется текущий опыт отдела радионуклидной диагностики и позитронно-эмиссионной томографии ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова» в выполнении сцинтиграфии миокарда с 99mTc-пирофосфатом при дифференциальной диагностике типов амилоидоза сердца. Проанализированы возможные причины ложноположительных, сомнительных и недиагностических результатов исследования, предложены способы их устранения, в том числе путем модификации протоколов планарного и томографического исследований и оптимизации диагностического алгоритма амилоидоза сердца в целом.
Ключевые слова: сцинтиграфия миокарда, амилоидоз сердца
Keywords: myocardial scintigraphy, cardiac amyloidosis
Ключевые слова: сцинтиграфия миокарда, амилоидоз сердца
________________________________________________
Keywords: myocardial scintigraphy, cardiac amyloidosis
Полный текст
Список литературы
1. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28(1):10-21. DOI:10.1016/j.tcm.2017.07.004
2. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017;84(12 Suppl. 3):12-26. DOI:10.3949/ccjm.84.s3.02
3. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75-84. DOI:10.1136/hrt.2009.190405
4. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166(17):1805-13. DOI:10.1001/archinte.166.17.1805
5. Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442-8. DOI:10.1136/heartjnl-2012-302353
6. Fontana M, Pica S, Reant P, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015;132(16):1570-9. DOI:10.1161/CIRCULATIONAHA.115.016567
7. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12. DOI:10.1161/CIRCULATIONAHA.108.843334
8. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26(6):2065-123. DOI:10.1007/s12350-019-01760-6
9. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-12. DOI:10.1161/CIRCULATIONAHA.116.021612
10. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076-84. DOI:10.1016/j.jacc.2005.05.073
11. Сергиенко В.Б., Терещенко С.Н., Аншелес А.А., и др. Радионуклидные методы в диагностике амилоидоза сердца. Рациональная фармакотерапия в кардиологии. 2018;14(1):94-100 [Sergienko VB, Tereshchenko SN, Ansheles AA, et al. Nuclear imaging in the diagnosis of cardiac amyloidosis. Rational Pharmacotherapy in Cardiology. 2018;14(1):94-100 (in Russian)]. DOI:10.20996/1819-6446-2018-14-1-94-100
12. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659-70. DOI:10.1016/j.jcmg.2011.03.016
13. Bokhari S, Castano A, Pozniakoff T, et al. 99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195-201. DOI:10.1161/circimaging.112.000132
14. Аншелес А.А., Сергиенко В.Б. Вопросы стандартизации метода нейротропной сцинтиграфии и однофотонной эмиссионной томографии миокарда с 123I-метайодбензилгуанидином. Вестник рентгенологии и радиологии. 2016;97(3):173-80 [Ansheles AA, Sergienko VB. Standardization of 123I-metaiodobenzylguanidine cardiac neurotropic scintigraphy and single-photon emission tomography. Vestnik Rentgenologii i Radiologii (Russian Journal of Radiology). 2016;97(3):173-80 (in Russian)].
DOI:10.20862/0042-4676-2016-97-3-173-180
15. Dorbala S, Ando Y, Bokhari S, et al. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2021;28(4):1769-74. DOI:10.1007/s12350-020-02455-z
2. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017;84(12 Suppl. 3):12-26. DOI:10.3949/ccjm.84.s3.02
3. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75-84. DOI:10.1136/hrt.2009.190405
4. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166(17):1805-13. DOI:10.1001/archinte.166.17.1805
5. Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442-8. DOI:10.1136/heartjnl-2012-302353
6. Fontana M, Pica S, Reant P, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015;132(16):1570-9. DOI:10.1161/CIRCULATIONAHA.115.016567
7. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12. DOI:10.1161/CIRCULATIONAHA.108.843334
8. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26(6):2065-123. DOI:10.1007/s12350-019-01760-6
9. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-12. DOI:10.1161/CIRCULATIONAHA.116.021612
10. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076-84. DOI:10.1016/j.jacc.2005.05.073
11. Sergienko VB, Tereshchenko SN, Ansheles AA, et al. Nuclear imaging in the diagnosis of cardiac amyloidosis. Rational Pharmacotherapy in Cardiology. 2018;14(1):94-100 (in Russian)]. DOI:10.20996/1819-6446-2018-14-1-94-100
12. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659-70. DOI:10.1016/j.jcmg.2011.03.016
13. Bokhari S, Castano A, Pozniakoff T, et al. 99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195-201. DOI:10.1161/circimaging.112.000132
14. Ansheles AA, Sergienko VB. Standardization of 123I-metaiodobenzylguanidine cardiac neurotropic scintigraphy and single-photon emission tomography. Vestnik Rentgenologii i Radiologii (Russian Journal of Radiology). 2016;97(3):173-80 (in Russian). DOI:10.20862/0042-4676-2016-97-3-173-180
15. Dorbala S, Ando Y, Bokhari S, et al. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2021;28(4):1769-74. DOI:10.1007/s12350-020-02455-z
2. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017;84(12 Suppl. 3):12-26. DOI:10.3949/ccjm.84.s3.02
3. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75-84. DOI:10.1136/hrt.2009.190405
4. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166(17):1805-13. DOI:10.1001/archinte.166.17.1805
5. Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442-8. DOI:10.1136/heartjnl-2012-302353
6. Fontana M, Pica S, Reant P, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015;132(16):1570-9. DOI:10.1161/CIRCULATIONAHA.115.016567
7. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12. DOI:10.1161/CIRCULATIONAHA.108.843334
8. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26(6):2065-123. DOI:10.1007/s12350-019-01760-6
9. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-12. DOI:10.1161/CIRCULATIONAHA.116.021612
10. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076-84. DOI:10.1016/j.jacc.2005.05.073
11. Сергиенко В.Б., Терещенко С.Н., Аншелес А.А., и др. Радионуклидные методы в диагностике амилоидоза сердца. Рациональная фармакотерапия в кардиологии. 2018;14(1):94-100 [Sergienko VB, Tereshchenko SN, Ansheles AA, et al. Nuclear imaging in the diagnosis of cardiac amyloidosis. Rational Pharmacotherapy in Cardiology. 2018;14(1):94-100 (in Russian)]. DOI:10.20996/1819-6446-2018-14-1-94-100
12. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659-70. DOI:10.1016/j.jcmg.2011.03.016
13. Bokhari S, Castano A, Pozniakoff T, et al. 99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195-201. DOI:10.1161/circimaging.112.000132
14. Аншелес А.А., Сергиенко В.Б. Вопросы стандартизации метода нейротропной сцинтиграфии и однофотонной эмиссионной томографии миокарда с 123I-метайодбензилгуанидином. Вестник рентгенологии и радиологии. 2016;97(3):173-80 [Ansheles AA, Sergienko VB. Standardization of 123I-metaiodobenzylguanidine cardiac neurotropic scintigraphy and single-photon emission tomography. Vestnik Rentgenologii i Radiologii (Russian Journal of Radiology). 2016;97(3):173-80 (in Russian)].
DOI:10.20862/0042-4676-2016-97-3-173-180
15. Dorbala S, Ando Y, Bokhari S, et al. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2021;28(4):1769-74. DOI:10.1007/s12350-020-02455-z
________________________________________________
2. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017;84(12 Suppl. 3):12-26. DOI:10.3949/ccjm.84.s3.02
3. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75-84. DOI:10.1136/hrt.2009.190405
4. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166(17):1805-13. DOI:10.1001/archinte.166.17.1805
5. Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442-8. DOI:10.1136/heartjnl-2012-302353
6. Fontana M, Pica S, Reant P, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015;132(16):1570-9. DOI:10.1161/CIRCULATIONAHA.115.016567
7. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12. DOI:10.1161/CIRCULATIONAHA.108.843334
8. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26(6):2065-123. DOI:10.1007/s12350-019-01760-6
9. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-12. DOI:10.1161/CIRCULATIONAHA.116.021612
10. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076-84. DOI:10.1016/j.jacc.2005.05.073
11. Sergienko VB, Tereshchenko SN, Ansheles AA, et al. Nuclear imaging in the diagnosis of cardiac amyloidosis. Rational Pharmacotherapy in Cardiology. 2018;14(1):94-100 (in Russian)]. DOI:10.20996/1819-6446-2018-14-1-94-100
12. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659-70. DOI:10.1016/j.jcmg.2011.03.016
13. Bokhari S, Castano A, Pozniakoff T, et al. 99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195-201. DOI:10.1161/circimaging.112.000132
14. Ansheles AA, Sergienko VB. Standardization of 123I-metaiodobenzylguanidine cardiac neurotropic scintigraphy and single-photon emission tomography. Vestnik Rentgenologii i Radiologii (Russian Journal of Radiology). 2016;97(3):173-80 (in Russian). DOI:10.20862/0042-4676-2016-97-3-173-180
15. Dorbala S, Ando Y, Bokhari S, et al. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2021;28(4):1769-74. DOI:10.1007/s12350-020-02455-z
Авторы
А.А. Аншелес*, С.Н. Насонова, И.В. Жиров, М.А. Саидова, О.В. Стукалова, С.Н. Терещенко, В.Б. Сергиенко
ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России, Москва, Россия
*a.ansheles@gmail.com
Chazov National Medical Research Center of Cardiology, Moscow, Russia
*a.ansheles@gmail.com
ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России, Москва, Россия
*a.ansheles@gmail.com
________________________________________________
Chazov National Medical Research Center of Cardiology, Moscow, Russia
*a.ansheles@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.